Founded in 2017, Wyvern Pharmaceuticals Inc. is a privately held biopharmaceutical company headquartered in Calgary, Canada. Our executive team brings together decades of experience in drug development and taking new therapies to market. Together, we aim to deliver meaningful quality of life and lifespan extension benefits to patient populations with serious unmet treatment needs. Our proprietary technologies use gene therapy to safely and effectively treat serious illnesses, including autoimmune disorders, cancer and infectious diseases. Our lead agent is WYV-RA, a gene therapy that treats rheumatoid arthritis by upregulating CTLA4 in target tissues, and downregulating TNF so that it is not excreted by the target tissues. Planning for a randomized clinical study in RA patients is now underway. Our follow-on agent is WYV-ONC, a gene therapy that treats cancer by upregulating TLR3 in target tumours and overcomes immunotherapy treatment resistance when used in combination with immunotherapies such as checkpoint inhibitors.